LetibotulinumtoxinA is a newly registered neuromodulator for the treatment of glabellar lines in Europe.*,2 Its efficacy and safety was evaluated in three identical randomized, double-blind, placebo-controlled, multicenter, phase 3 studies including more than 1.200 patients.2

Results from the most recent study have now been published in the Aesthetic Surgery Journal (Mueller DS, Prinz V, Adelglass J, Cox SE, Gold M, Kaufman-Janette J et al. Efficacy and Safety of Letibotulinum Toxin A in the Treatment of Glabellar Lines: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study. Aesthet Surg J. 2022; 42(6): 677- 88) and support the high efficacy and a convincing safety profile of letibotulinumtoxinA in the treatment of glabellar lines:*

  • Response rate for letibotulinumtoxinA subjects reached 94 % at Week 4 after injection**, with a treatment duration of 4 months1,***
  • Median time to onset was 3 days, with almost 1 out of 4 patients reporting a ≥ 1-point reduction in FWS already within the first 24 hours after injection1
  • LetibotulinumtoxinA was effective even in severe glabellar lines, achieving no or minimal lines at Week 4 in 48.5% of patients who had severe lines at baseline1
  • LetibotulinumtoxinA was well-tolerated with a low incidence of treatment-emergent adverse events1
  • The study also demonstrated consistent efficacy and safety of letibotulinumtoxinA with repeated injections for up to 12 months.1,2

Based on these results the authors concluded a high efficacy and excellent safety profile for letibotulinumtoxinA in the treatment of glabellar lines.*

In Europe this newly registered neuromodulator is now becoming available for aesthetic professionals as Letybo®, marketed by Croma-Pharma.

* Letybo® is indicated for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows in adults < 75 years old seen at maximum frown (glabellar lines), when the severity of the facial lines has an important psychological impact.

** Response rate was defined as a ≥ 1-point reduction in Facial Wrinkle Scale (FWS) at maximum frown based on the investigators assessment.

*** Assessed by the number of subjects having a ≥ 2-point reduction in FWS with a rating of 0 or 1 at a given timepoint; the timepoint when this value was still statistically significant vs. placebo was 16 weeks

References:

  1. Mueller DS, Prinz V, Adelglass J, Cox SE, Gold M, Kaufman-Janette J et al. Efficacy and Safety of Letibotulinum Toxin A in the Treatment of Glabellar Lines: A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study. Aesthet Surg J. 2022; 42(6): 677- 88
  2. Letybo® smPC, April 2022, https://www.medicines.org.uk/emc/product/13707